Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombotics and thrombolytics in stroke.

Shaker A Mousa1, Omar Iqbal, Jawed Fareed

  • 1Albany College of Pharmacy, NY 12208-3492, USA. mousas@acp.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|July 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism.

Research and practice in thrombosis and haemostasis·2026
Same author

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Cancers·2026
Same author

Bone Regeneration Techniques for Dental Implant Placement Comparing the Effect of Graft Material on Bone Volume and Long-Term Graft Stability: A Systematic Review.

The Journal of oral implantology·2026
Same author

A Comparative Study of Porcine and Ovine Derived Defibrotide: Coagulation Profiles, Molecular Characteristics, and DNA Content.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Circulating Exosomal MicroRNAs as Potential Biomarkers for Pulmonary Embolism.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Multifactorial thrombotic risk in Evans syndrome: a case report and review of the literature.

Thrombosis journal·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Standardizing antithrombotic and antiplatelet therapies for stroke is crucial. Platelet glycoprotein (GP) IIb/IIIa antagonists show promise for preventing re-occlusion during interventions, but hemorrhage risk varies.

Area of Science:

  • Neuroscience
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cerebrovascular interventions like angioplasty and stenting are increasingly common for stroke treatment.
  • Standardized antithrombotic and antiplatelet regimens are lacking for these procedures.
  • Clinical presentation and lesion characteristics influence the safety and efficacy of antithrombotic therapies.

Purpose of the Study:

  • To review the prophylactic use of antithrombotics in stroke patients undergoing interventions.
  • To compare the benefits and risks of thrombolytics versus other antithrombotic strategies.
  • To evaluate the potential role of platelet glycoprotein (GP) IIb/IIIa receptor antagonists.

Main Methods:

  • Literature review of antithrombotic and antiplatelet therapies in cerebrovascular interventions.

Related Experiment Videos

  • Analysis of safety and efficacy data for various antithrombotic agents.
  • Comparison of thrombolytics with GP IIb/IIIa antagonists in acute stroke intervention.

    • Main Results:

    • Platelet GP IIb/IIIa antagonists may offer value as monotherapy or adjunctive treatment.
    • Higher risk of cerebral hemorrhage observed in acute stroke patients compared to TIA or partial occlusion.
    • GP IIb/IIIa antagonists show potential in reducing re-occlusion rates for high-risk lesions (e.g., basilar artery, carotid occlusion).

    Conclusions:

    • Antithrombotic and antiplatelet therapy selection requires careful consideration of patient factors and lesion characteristics.
    • Platelet GP IIb/IIIa antagonists represent a promising therapeutic option for specific cerebrovascular interventions.
    • Further research is needed to standardize antithrombotic regimens and optimize outcomes in stroke intervention.